Niraparib Global Buyers List: Comprehensive Guide for Pharma Sourcing Professionals

Niraparib, marketed globally under the brand name Zejula, is a potent poly (ADP-ribose) polymerase (PARP) inhibitor primarily indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. Originally developed by Tesaro and now commercialized by GlaxoSmithKline (GSK), Niraparib has become one of the leading PARP inhibitors in the global oncology market. With the Niraparib industry revenue expected to reach approximately $1.4 billion in 2025 and projected to grow at a 7.1% CAGR through 2034, understanding the global buyer landscape is essential for pharmaceutical companies, API manufacturers, and distributors seeking to enter or expand in this market.

This comprehensive guide provides a detailed overview of the Niraparib global buyers list, covering major purchasers, importers, distributors, and key stakeholders across the pharmaceutical supply chain.

Global Niraparib Market Overview

Market Size and Growth Trajectory

The global Niraparib market has demonstrated robust growth, driven by increasing adoption of precision oncology therapies and rising prevalence of ovarian and related gynecological cancers worldwide. The Niraparib Tosylate market alone was projected at $311.1 million in 2025, with expectations to reach $1.35 billion by 2033, growing at a CAGR of 20.18%. The broader Niraparib market is estimated to grow from $1.3 billion in 2024 to $2.6 billion by 2034.

Key growth drivers include:

Increasing emphasis on targeted cancer treatment strategies
Growing awareness regarding genetic testing and biomarker-driven oncology
Expanding therapeutic applications beyond ovarian cancer
Supportive regulatory approvals and reimbursement frameworks

Competitive Landscape

GSK’s Zejula (niraparib) holds approximately 28% market share with over $1.6 billion in sales, making it the second-leading PARP inhibitor behind AstraZeneca’s Lynparza (olaparib). Major players in the Niraparib ecosystem include Janssen Biotech, Takeda Pharmaceutical, and Zai Lab (再鼎医药) in the Chinese market .

Comprehensive Niraparib Global Buyers List

1. Major Pharmaceutical Companies & Brand Holders

GlaxoSmithKline (GSK)
GSK is the primary commercial rights holder for Zejula globally. The company manages the brand’s distribution through its extensive pharmaceutical network and is a key buyer of Niraparib API and finished dosage forms for global commercialization.

Janssen Biotech (Johnson & Johnson)
Janssen Biotech co-commercializes Niraparib in certain regions and markets the combination product AKEEGA (niraparib and abiraterone acetate). As a major buyer and distributor, Janssen plays a significant role in the Niraparib supply chain.

Takeda Pharmaceutical
Takeda is another key player in the Niraparib market, involved in regional commercialization and distribution .

Zai Lab (再鼎医药)
Zai Lab holds the rights to Niraparib (marketed as Zejula/则乐 in China) and is a major buyer for the Chinese market.

Merck Sharp & Dohme (MSD)
MSD is involved in the development and commercialization of Niraparib in certain territories.

2. API Manufacturers and Suppliers (Serving as Buyers of Raw Materials)

The following companies are significant buyers of Niraparib intermediates, raw materials, and related compounds for their manufacturing operations:

Valary Lab Pvt Ltd (India)
Active with 78 transactions involving Niraparib Tosylate Monohydrate. Located in India, Valary Lab is a prominent player in the Niraparib API supply chain.

Novick Bio Sciences Pvt Ltd (India)
With 1,045 transactions, Novick Bio Sciences is one of the most active buyers in the Niraparib ecosystem.

Criticalkare Pharma (India)
Engaged in 43 transactions for Niraparib 100mg Capsules, this company is an active participant in the finished dosage form market.

Porton Pharma Solutions Ltd (China)
A major Chinese player with 139 transactions in Niraparib Tosylate. Porton is both a supplier and buyer in the global API market.

GlaxoSmithKline R&D Ltd (England)
GSK’s R&D division actively procures Niraparib for clinical research and development purposes.

Mayne Pharma Ltd (Australia/United States)
With 301 transactions, Mayne Pharma is a significant buyer of Niraparib Tosylate Monohydrate .

ScinoPharm Taiwan
A key API manufacturer and buyer in the Asian market.

Zhejiang Tuopu Pharmaceutical (China)
An important Chinese player in the Niraparib tosylate market.

Teva API
The global generic pharmaceutical giant is a significant participant in the Niraparib API market.

Shengda Pharmaceutical Co (China)
Active in Niraparib-related transactions.

Biophore India Pharmaceuticals Pvt Ltd
A verified manufacturer and buyer of Niraparib API with Drug Master File (DMF) submissions.

Sichuan Qingmu Pharmaceutical (China)
A Chinese manufacturer and buyer of Niraparib-related products.

Changzhou Pharmaceutical Factory (China)
A major Chinese producer with USDMF and CoA certifications.

Cipla Limited (India)
One of India’s largest pharmaceutical companies, actively involved in the Niraparib API market with USDMF and CoA certifications.

3. Distributors and Specialty Pharmacies

McKesson Specialty Health
Selected by Tesaro as one of Zejula’s distributors of choice for in-office dispensing practices.

ASD Healthcare
A specialty distributor for AKEEGA (niraparib and abiraterone acetate).

Besse Medical
Another specialty distributor for Niraparib combination products.

CuraScript SD
A specialty distributor involved in Niraparib distribution.

Myonex, LLC (United States)
Active with 34 transactions involving AKEEGA (niraparib and abiraterone acetate).

M/S Sunsource Pharmaceuticals (United States)
Engaged in 12 transactions involving AKEEGA Tablets.

Divine Pharma Solutions LLC (United States)
An active participant with 7 transactions in the Niraparib market.

4. International Buyers and Importers by Region

North America

United States
The U.S. is one of the top markets for Niraparib, expected to observe growth at a CAGR of 4.6% to 6.8% between 2024 and 2030. Key buyers include QS Pharma LLC and various specialty distributors and hospital pharmacies.

Canada
Canadian buyers include Candiac, which has been involved in Niraparib Tosylate Monohydrate imports.

Europe

Slovenia
Multiple buyers based in Slovenia include Ziga Gerbec (Logisticna Tocka), Pija Kosir (Analytics, Stability), Sandoz Development Center, and Gerbec Ziga Lek Pharmaceuticals. These buyers typically procure Niraparib for research, testing, and stability studies.

Greece
Pharos, with 1,699 transactions, is a significant buyer of Niraparib placebo and related products.

Ireland
SK Biotek Ireland Ltd is involved in Niraparib-related substance procurement.

United Kingdom
GSK R&D Ltd and other pharmaceutical entities are active buyers in the UK market.

Asia-Pacific

China
The Chinese market is one of the top markets for Niraparib. Key buyers include:

Zai Lab (commercial rights holder)
Quest Pharmaceutical Services Co Ltd (Taiwan)
Various hospital pharmacies including Sinopharm Holding Hunan Weian Pharmacy

India
India leads in Niraparib imports with 28.48% of global import share. Major Indian buyers include Valary Lab Pvt Ltd, Novick Bio Sciences, Criticalkare Pharma, Natco Pharma Ltd, and Cipla Limited.

Pakistan
Individual buyers such as Asad Ali Sheikh and Kashif Hayat have been identified as procurers of Niraparib 100mg capsules.

Kenya
Miriam Nanyunja is an identified buyer in the Kenyan market.

5. Research and Clinical Trial Buyers

Several entities procure Niraparib exclusively for research and clinical trial purposes:

Ziga Gerbec (Slovenia): Testing and research purposes
Pija Kosir (Slovenia): Analytical and stability testing
Mayne Pharma Ltd: Analytical testing purposes
Quest Pharmaceutical Services Co Ltd: Research standard procurement

6. Generic Manufacturers and Emerging Market Buyers

Several bioequivalent generic versions of Niraparib are available from manufacturers in Bangladesh, India, and Laos, including:

Beacon Pharmaceuticals (Bangladesh)
Everest Pharmaceuticals Limited

Procurement and Sourcing Channels

API and Raw Material Procurement

For pharmaceutical companies and API manufacturers seeking to buy Niraparib or its intermediates, several verified platforms and channels exist:

Pharmaoffer: A platform covering over 4,000 APIs with commercial-scale suppliers from India and China
Pharmacompass: Provides access to Drug Master Files (DMF) and Certificate of Suitability (CEP) information for Niraparib API suppliers
52WMB: An import-export data platform providing real-time buyer and supplier information with transaction histories

Finished Dosage Form Procurement

For healthcare providers and pharmacies:

Hospital pharmacies remain the primary channel for Niraparib procurement
Specialty distributors like McKesson Specialty Health, ASD Healthcare, and Besse Medical serve as key distribution channels
Retail pharmacies in various countries dispense Niraparib by prescription

Regional Distribution Dynamics

Trade data reveals that India leads in Niraparib exports (43.67%) and imports (28.48%). Other major importing countries include the United States, Slovenia, and various European nations. The Niraparib market operates with seven active exporters and a top-3 concentration of 91%, indicating that the buyer’s spend concentrates on three primary suppliers.

Key Considerations for Niraparib Buyers

Regulatory and Compliance Factors

Niraparib is a prescription-only medicine in most jurisdictions. Buyers must ensure compliance with local regulatory requirements, including:

Valid prescription requirements
Import/export licenses for pharmaceutical products
Compliance with Good Distribution Practice (GDP) guidelines
Adherence to local pricing and reimbursement regulations

Quality and Certification Requirements

API buyers should verify that suppliers hold appropriate certifications:

USDMF (United States Drug Master File)
CEP (Certificate of Suitability)
GMP (Good Manufacturing Practice)
CoA (Certificate of Analysis)

Market Trends and Future Outlook

Buyers and procurement professionals should monitor several key trends:

Expanding indications: Niraparib is being investigated for broader oncology applications including prostate and breast cancer
Combination therapies: Growing adoption of combination therapies with immuno-oncology agents like Jemperli (dostarlimab)
Emerging markets: Countries including Nigeria, Indonesia, and Colombia are expected to observe the highest growth with CAGRs ranging between 8.2% to 9.8%
Generic competition: Bioequivalent generic versions are increasingly available from manufacturers in Bangladesh, India, and Laos
Precision oncology transition: The shift from broad-spectrum chemotherapy to precision oncology approaches is expected to add $62 million of additional value to Niraparib industry revenue by 2030

ООО КОРЕКС
NATCO PHARMA LIMITED
JANSSEN CILAG SA DE CV
JOHNSON JOHNSON PRIVATE LIMITED
SUN PHARMACEUTICAL INDUSTRIES LIMITED
SANDOZ PRIVATE LIMITED
JANSSEN CILAG FARMACEUTICA SOCIEDAD ANONIMA
DR REDDY S LABORATORIES LTD
EVEREST PHARMACEUTICALS LIMITED
JENPHAR BANGLADESH LIMITED CHANGED
CIPLA LIMITED
GSK PHARMA INDIA PRIVATE LIMITED
NOVICK BIO SCIENCES PRIVATE LIMITED
HETERO LABS LIMITED
LABORATORIO ECZANE PHARMA S A
ПРЕДСТАВНИЦТВО ЯНССЕН ФАРМАЦЕВТИКА НВ ВУЛ СПАСЬКА 30 КИЇВ 04070 УКРАЇНА
ТОВ КОРЕКС УКРАЇНА 08114 КИЇВСЬКА ОБЛ С ГОРЕНИЧІ ВУЛ СТОЛИЧНА БУД 1А
ADIUM PHARMA S A
BEACON PHARMACEUTICALS PLC
COMERCIAL FARMACEUTICA LEISA SOCIEDAD AN
HIMMEL PHARMACEUTICALS PVT LIMITED
GLOBAL PHARMA LTDA
INCEPTA PHARMACEUTICALS LIMITED
INTAS PHARMACEUTICALS LIMITED
LIFE TECHNOLOGIES INDIA PRIVATE LIMITED
MRS DAISY AJAY CHOKSI
MSN LABORATORIES PRIVATE LIMITED
ROMERO HERNANDEZ ALBA MILENA
SABORIO CONEJO YAMILETH
BIOORGANICS AND APPLIED MATERIALS PRIVATE LIMITED
CARVAJAL GONZALEZ MIRIAM JEANNETTE
COREX LLC
CÔNG TY TRÁCH NHIỆM HỮU HẠN SINH DƯỢC PHẨM HERA
EUROFARMA URUGUAY SOCIEDAD ANONIMA
GLAXOSMITHKLINE PHARMACEUTICALS COSTA RICA SOCIEDAD ANONIMA
LABORATORIOS JAYOR S R L
MIRIAM NANYUNJA
MRS DAISY AJAY CHOKSHI
QUIMFA S A
ROEMMERS S A
VEEDA CLINICAL RESEARCH LIMITED
ZISKA PHARMACEUTICALSLIMITED
ZYDUS LIFESCIENCES LIMITED
AET LABORATORIES PRIVATE LIMITED
COMERCIAL FARMACEUTICA LEISA SOCIEDAD ANONIMA
DR REDDY S LABORATORIES LIMITED
GLAXOSMITHKLINE CHILE FARMACEU
GLAXOSMITHKLINE COLOMBIA SA
GLOBAL MEDICAL LOGISTICS SOCIEDAD ANONIMA
GRAMON BAGO DE URUGUAY S A
GUILLERMO HUGO DOMINGUEZ Y GARCIA
ICU VITA S A
JOHNSON AND JOHNSON SIHHI MALZEME SANAYI VE TICARET LIMITED SIRKETI
KAIZEN PHARMACEUTICALS PVT LTD
LABORATORIO GADOR S A
M S ROTEX PHARMA PVT LIMITED
MARIA RODRIGUEZ
MARIA RODRIGUEZ RUC 961941
NOBEL ILAC SANAYII VE TICARET ANONIM SIRKETI
ONCOVANZ PHARMACEUTICALS PRIVATE LIMITED
QUEHENBERGER LOGISTICS BEL FOR IMP LOGISTICS BEL
RODRIGUEZ CERVANTES SILVIA DORA
TRESA ARTIGAS LTDA
URUFARMA S A
WIERNIK LIPIEC JEANINA
WORLD MEDICINE ILAC SANAYI VE TICARET ANONIM SIRKETI
ООО АВТОБАЙ
ООО ГЕСС СИАЙЭС
ООО ПЛАМБЕРИЯ
ООО ХЕТТИХ РУС
ПРЕДСТАВНИЦТВО ЯНССЕН ФАРМАЦЕВТИКА НВ 04070 МІСТО КИЇВ ВУЛИЦЯ СПАСЬКА БУДИНОК 30 УКРАЇНА
ТОВ КОРЕКС УКРАЇНА 08114 КИЇВСЬКА OБЛ С ГOРЕНИЧІ ВУЛ СТOЛИЧНА БУД 1 А

Conclusion

The global Niraparib buyer landscape is diverse, spanning major pharmaceutical corporations, API manufacturers, specialty distributors, research institutions, and healthcare providers across North America, Europe, and Asia-Pacific. With the market projected to reach $2.6 billion by 2034, understanding the buyer ecosystem is essential for successful market entry and expansion.

Key takeaways for sourcing professionals:

India and China remain the primary sources for Niraparib API procurement
The United States and China are the largest end-market buyers
Verified platforms like Pharmaoffer and Pharmacompass provide access to qualified suppliers
Regulatory compliance and quality certifications are non-negotiable requirements
Emerging markets present significant growth opportunities for Niraparib buyers and suppliers

For pharmaceutical companies, distributors, and healthcare providers seeking to navigate the Niraparib global market, this buyers list serves as a foundational resource for identifying key stakeholders and building strategic partnerships in this rapidly growing oncology sector.